PMID- 21167340
OWN - NLM
STAT- MEDLINE
DCOM- 20110223
LR  - 20170203
IS  - 1097-6744 (Electronic)
IS  - 0002-8703 (Linking)
VI  - 161
IP  - 1
DP  - 2011 Jan
TI  - CD34(+) cell infusion after ST elevation myocardial infarction is associated with 
      improved perfusion and is dose dependent.
PG  - 98-105
LID - 10.1016/j.ahj.2010.09.025 [doi]
AB  - BACKGROUND: the objective of the study was to determine whether the effects of 
      infarct-related artery (IRA) infusion of autologous bone marrow-derived CD34(+) 
      cells after ST elevation myocardial infarction (STEMI) are dependent on the dose 
      (quantity and mobility) of the cells infused. Beneficial effects of IRA infusion 
      of mononuclear cells after STEMI have been inconsistent, possibly because of 
      differences in timing, cell type, quantity, and mobility of infused cells. 
      METHODS: patients were randomized to bone marrow harvest (n = 16) or control (n = 
      15). At a median of 8.3 days after coronary stenting for STEMI, CD34(+) cells 
      were infused via the IRA at 3 dose levels (5, 10, and 15 x 10(6)) in cohorts of 5 
      patients each. Baseline and follow-up imaging and ex vivo CD34(+) cell mobility 
      were performed. RESULTS: Cell harvest and infusion were safe. Quantitative rest 
      hypoperfusion score measured by single-photon emission computed tomography 
      improved at 6 months in the >/= 10 million cohorts compared with controls (-256 vs 
      +14, P = .02). There was a trend toward improved ejection fraction at 6 months 
      (+4.5%) in the >/= 10 million cohorts compared with no change in the controls and 5 
      million cohort (+0.7%). Improved perfusion and infarct size reduction correlated 
      with the quantity and mobility of the infused CD34(+) cells. CONCLUSIONS: the 
      effects of CD34(+) cell IRA infusion during the repair phase after STEMI are dose 
      dependent and, at a threshold dose of 10 million CD34(+) cells, associated with a 
      significant improvement in perfusion that may limit deterioration in cardiac 
      function (IRA infusion of CD34(+) cells in patients with acute myocardial 
      infarction [AMR-01] NCT00313339).
FAU - Quyyumi, Arshed A
AU  - Quyyumi AA
AD  - Emory University, Atlanta, GA, USA. aquyyum@emary.edu
FAU - Waller, Edmund K
AU  - Waller EK
FAU - Murrow, Jonathan
AU  - Murrow J
FAU - Esteves, Fabio
AU  - Esteves F
FAU - Galt, James
AU  - Galt J
FAU - Oshinski, John
AU  - Oshinski J
FAU - Lerakis, Stamatios
AU  - Lerakis S
FAU - Sher, Salman
AU  - Sher S
FAU - Vaughan, Douglas
AU  - Vaughan D
FAU - Perin, Emerson
AU  - Perin E
FAU - Willerson, James
AU  - Willerson J
FAU - Kereiakes, Dean
AU  - Kereiakes D
FAU - Gersh, Bernard J
AU  - Gersh BJ
FAU - Gregory, Douglas
AU  - Gregory D
FAU - Werner, Astrid
AU  - Werner A
FAU - Moss, Thomas
AU  - Moss T
FAU - Chan, Wai Shun
AU  - Chan WS
FAU - Preti, Robert
AU  - Preti R
FAU - Pecora, Andrew L
AU  - Pecora AL
LA  - eng
SI  - ClinicalTrials.gov/NCT00313339
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
RN  - 0 (Antigens, CD34)
SB  - IM
MH  - *Antigens, CD34
MH  - Bone Marrow Cells/*immunology
MH  - Bone Marrow Transplantation/*methods
MH  - Coronary Circulation/*physiology
MH  - Coronary Vessels
MH  - *Electrocardiography
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Infusions, Intra-Arterial
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/diagnosis/physiopathology/*therapy
MH  - Tomography, Emission-Computed, Single-Photon
MH  - Treatment Outcome
EDAT- 2010/12/21 06:00
MHDA- 2011/02/24 06:00
CRDT- 2010/12/21 06:00
PHST- 2010/04/07 00:00 [received]
PHST- 2010/09/29 00:00 [accepted]
PHST- 2010/12/21 06:00 [entrez]
PHST- 2010/12/21 06:00 [pubmed]
PHST- 2011/02/24 06:00 [medline]
AID - S0002-8703(10)00894-X [pii]
AID - 10.1016/j.ahj.2010.09.025 [doi]
PST - ppublish
SO  - Am Heart J. 2011 Jan;161(1):98-105. doi: 10.1016/j.ahj.2010.09.025.